Results 311 to 320 of about 825,494 (348)
Some of the next articles are maybe not open access.
Chronic oral etoposide in non-small cell lung carcinoma
European Journal of Cancer, 199225 consecutive inoperable or extended non-small cell lung cancer (NSCLC) patients (19 non-chemotherapy pretreated, 6 non-heavily pretreated) were given oral etoposide, 50 mg/m2/day for 21 successive days, every 4 weeks. 5 partial responses (PR), 9 disease stabilizations were achieved; the overall response rate of 20% (95% confidence interval, 4% to 36%)
J, Estapé +9 more
openaire +2 more sources
Unresectable non-small cell lung carcinoma
Revisiones en Cáncer, 2023Ivana Sullivan +2 more
openaire +1 more source
[Diagnostics of non-small cell lung carcinoma].
Duodecim; laaketieteellinen aikakauskirja, 2014ALK inhibitor therapy is individual cancer treatment, in which the targeted drug therapy is directed to a patient group that is likely to benefit from the therapy. The detection in the tumor of ALK gene (anaplastic lymphoma kinase) rearrangement is a prerequisite for the ALK inhibitor therapy for non-small cell lung carcinoma.
Kaisa, Salmenkivi, Aija, Knuuttila
openaire +1 more source
Non-small cell lung carcinoma. Clinical case
Filin’s Clinical endoscopyIn 2020, 2.2 million new cases of lung cancer were reported. The main form of lung cancer is non-small cell carcinoma (85%). Non-small cell lung cancer has 3 subtypes: adenocarcinoma, large cell and squamous cell carcinoma. Squamous cell lung cancer occurs in 20-40% of all lung cancers.
openaire +1 more source